With Gilead Sciences (NSDQ:GILD) and Novartis (NYSE:NVS) leading the way, cell therapies are moving on to the market and into the clinics for patients that have no other option. Companies making CAR-T therapies use a patient’s own cells to genetically engineer a cancer-killing cellular therapy that is then delivered back to the patient.
And one 55-person company is responsible for getting those products safely from the manufacturer to the patient.
Get the full story at our sister site, Drug Delivery Business News.
The post This company helps cell therapies travel around the world appeared first on MassDevice.